EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs

Nasser Alotaiq iD, Doni Dermawan iD

International Journal of Molecular Sciences · 18.12.2025 · 26 (24) · 12159

DOI: 10.3390/ijms262412159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.12.2025. Verfasst von Nasser Alotaiq und 1 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia. Hauptthemen laut MEDLINE: Biological Products, Lactones, Proteasome Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The proteasome β5 subunit plays a central role in protein degradation and is an established therapeutic target in glioblastoma. Marizomib (MZB), a natural β5 inhibitor, has shown promising anticancer activity, yet suboptimal pharmacological properties limit its clinical translation. Using a comprehensive computational approach, this study aimed to identify and characterize novel MZB analogs with improved binding affinity, stability, and drug-like profiles. An integrative in silico study was performed, including molecular docking, frontier molecular orbital (FMO) analysis, pharmacophore modeling, molecular dynamics (MD) simulations over 200 ns, MM/PBSA binding free energy calculations, and per-residue energy decomposition. ADMET profiling evaluated the pharmacokinetic and safety properties of MZB and top-performing analogs. Docking and pharmacophore modeling revealed strong complementarity between MZB analogs and the β5 catalytic pocket. MD simulations showed that MZBMOD-77 and MZBMOD-79 exhibited exceptional structural stability with low RMSD values (0.40–0.42 nm), persistent binding within the active site cavity, and significant disruption of hydrogen-bond networks in the active loop regions Ala19–Lys33 and Val87–Gly98. MM/PBSA analysis confirmed their superior binding free energies (−19.99 and −18.79 kcal/mol, respectively), surpassing native MZB (−6.26 kcal/mol). Per-residue decomposition highlighted strong contributions from Arg19, Ala20, Lys33, and Ala50. ADMET predictions indicated improved oral absorption, reduced toxicity, and favorable pharmacokinetics compared to native MZB. This integrative computational study identifies MZBMOD-77 and MZBMOD-79 as promising next-generation proteasome β5 inhibitors. These analogs mimic and enhance the inhibitory mechanism of native MZB, offering potential candidates for further optimization and preclinical development in glioblastoma therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsLactonesProteasome InhibitorsAntineoplastic AgentsMolecular Docking SimulationMolecular Dynamics SimulationHumansDrug DesignProteasome Endopeptidase ComplexAnimalsPyrroles

Stichwörter der Autor:innen

20S proteasome β5 subunitfrontier molecular orbitalglioblastomamarizomibmolecular dynamicspharmacophore

Substanzen

Biological ProductsmarizomibLactonesProteasome InhibitorsProteasome Endopeptidase ComplexAntineoplastic AgentsPyrroles

Autor:innen und Institutionen

  • Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
  • Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.

ORCID-Profile: Nasser Alotaiq, Doni Dermawan

Förderung

  • Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)

Zitieren

APA

Alotaiq, N., & Dermawan, D. (2025). From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs. International Journal of Molecular Sciences, 26(24), 12159. https://doi.org/10.3390/ijms262412159

Vancouver

Alotaiq N, Dermawan D. From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs. International Journal of Molecular Sciences. 2025;26(24):12159. doi:10.3390/ijms262412159

BibTeX
@article{Alotaiq2025,
  author = {Alotaiq, Nasser and Dermawan, Doni},
  title = {From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {24},
  pages = {12159},
  doi = {10.3390/ijms262412159}
}
Kostenlos starten →